NSC-125973 |
BMS-181339-01 |
TAXOL 100 |
ABRAXANE |
DHP 107 |
NK 105 |
ABI-007 |
TAXOL |
BMS 181339-01 |
QW-8184 |
MBT 0206 |
PACITAXEL |
PAXENE |
PACLITAXEL |
INTAXEL |
CAPXOL |
MITOTAX |
CYCLOPAX |
GENEXOL |
LIPOPAC |
ANZATAX |
ONXOL |
TAXALBIN |
GENETAXYL |
TAXOL A |
PLAXICEL |
YEWTAXAN |
5BETA,20-EPOXY-1,2-ALPHA,4,7BETA,10BETA,13ALPHA-HEXAHYDROXYTAX-11-EN-9-ONE 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE |
EBETAXEL |
chembl:CHEMBL428647 |
drugbank:01229 |
rxcui:56946 |
chemidplus:33069-62-4 |
pubchem.compound:36314 |
Year of Approval | 1992 |
Drug Class | antineoplastic agents |
Drug Indications | for treatment of peripheral arterial disease (PAD) |
Drug Indications | antiinflammatory agent,DMARD |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antineoplastic agent |
Drug Categories | agents causing muscle toxicity |
Drug Categories | bsep/abcb11 substrates |
Drug Categories | bsep/abcb11 substrates with narrow therapeutic index |
Drug Categories | cardiotoxic antineoplastic agents |
Drug Categories | cytochrome p-450 cyp2c8 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inducers |
Drug Categories | cytochrome p-450 cyp3a4 inducers (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a5 substrates |
Drug Categories | cytochrome p-450 cyp3a5 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 cyp3a7 substrates |
Drug Categories | cytochrome p-450 cyp3a7 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 enzyme inducers |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | microtubule inhibition |
Drug Categories | microtubule inhibitors |
Drug Categories | narrow therapeutic index drugs |
Drug Categories | neurotoxic agents |
Drug Categories | oatp1b3 substrates |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | p-glycoprotein substrates with narrow therapeutic index |
n/a |
inhibitor (inhibitory) |
Trial Name | oral paclitaxel |
Novel drug target | Established target |
Trial Name | Abraxane |
n/a |
inhibitor (inhibitory) |
Mechanism of Interaction | Tubulin inhibitor |
Direct Interaction | yes |
Drug family | Taxane |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Details of Interaction | Mitotic cell cycle arrest in A431 cells |
Endogenous Drug? | False |
n/a |
n/a |
combination therapy | Sapitinib + Paclitaxel |
Indication/Tumor Type | inflammatory breast carcinoma |
Response Type | sensitive |
n/a |
combination therapy | Carboplatin + Paclitaxel + Veliparib |
Indication/Tumor Type | breast cancer |
Response Type | predicted – sensitive |
agonist (activating) |
inducer (activating) |
Specific Action of the Ligand | Agonist |
Endogenous Drug? | False |
n/a |
combination therapy | Ipatasertib + Paclitaxel |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | predicted – sensitive |
n/a |
Trial Name | liposomal encapsulated paclitaxel (LEP) |
Novel drug target | Established target |
PACLITAXEL | DrugBank Drug Name |
33069-62-4 | CAS Number |
Abraxane | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | vet_approved |
PACLITAXEL | Primary Drug Name |
Drug Class | antineoplastic agents |
Year of Approval | 1992 |
Drug Indications | antineoplastic agent |
Drug Class | Small Molecule |
FDA Approval | approved |
C1411 | NCI drug code |
CHEMBL428647 | ChEMBL Drug ID |
C1411 | NCI drug code |
PACLITAXEL | GuideToPharmacology Ligand Name |
D0C4RB | TTD Drug ID |